Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-30
DOI
10.1111/joim.13738
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
- (2023) Hua Jin et al. Journal of Hematology & Oncology
- The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
- (2023) Matteo Piccini et al. Bioengineering
- Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
- (2023) Li Xuan et al. Lancet Haematology
- Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib
- (2022) Catherine C. Smith et al. Blood Advances
- Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
- (2022) Alexander E. Perl et al. Blood Cancer Journal
- Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1
- (2022) Maike Janssen et al. BLOOD
- Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel
- (2022) Hartmut Döhner et al. BLOOD
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- (2022) Naval Daver et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
- (2022) Nikolaus Jahn et al. LEUKEMIA
- Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia
- (2022) Guangyang Weng et al. JOURNAL OF INTERNAL MEDICINE
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
- (2021) Christoph Röllig et al. LEUKEMIA
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
- (2021) Abhishek Maiti et al. Blood Cancer Journal
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
- (2021) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
- (2021) Yuanfei Shi et al. Frontiers in Oncology
- Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
- (2020) Yu-Wen Wang et al. ANNALS OF HEMATOLOGY
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
- (2020) Raghuveer Singh Mali et al. HAEMATOLOGICA
- Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
- (2020) Seth E Karol et al. LANCET ONCOLOGY
- Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
- (2020) Iman Abou Dalle et al. Blood Cancer Journal
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
- (2020) Lindsey T. Brinton et al. Journal of Hematology & Oncology
- Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor
- (2019) Xin-Jie Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2019) Li Xuan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2019) Ibrahim Aldoss et al. AMERICAN JOURNAL OF HEMATOLOGY
- Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia
- (2019) Jun Ma et al. CLINICAL CANCER RESEARCH
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3
- (2019) Chunxiao Zhang et al. CANCER
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
- (2019) Konstanze Döhner et al. BLOOD
- Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
- (2018) Li Xuan et al. CANCER
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
- (2017) M Wattad et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies
- (2017) Stephen E. Kurtz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT
- (2016) Francesco Saraceni et al. Journal of Hematology & Oncology
- Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
- (2015) Nelli Bejanyan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
- (2015) M. Klanova et al. CLINICAL CANCER RESEARCH
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations
- (2014) Yesid Alvarado et al. CANCER
- Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
- (2014) K D Cummins et al. Blood Cancer Journal
- Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD
- (2013) Koichi Takahashi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial
- (2013) Jie Jin et al. LANCET ONCOLOGY
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
- (2011) P Chevallier et al. LEUKEMIA
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started